share_log

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

Benzinga ·  Nov 27 00:47  · Ratings

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $102 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment